21 The Multiple Comparison Issue in Health Care Research

Handbook of Statistics

Volumn 27, Issue , 2007, Pages 616-655

  Moyé, Lemuel A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649337295     PISSN: 01697161     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0169-7161(07)27021-X     Document Type: Review

References (84)

1. Adams, C. (2002). At FDA, approving cancer treatments can be an ordeal. The Wall Street Journal December 11, 1.
2. Anonymous. Evidence of cause and effect relationship in major epidemiologic study disputed by judge. Epidemiology Monitor 9 (1988) 1
3. Assmann S., Pocock S., Enos L., and Kasten L. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355 (2000) 1064-1069
4. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological) 57 1 (1995) 289-300
5. Benjamini Y., and Yekutieli D. The control of the false discovery rate in multiple testing under dependency. The Annals of Statistics 29 4 (2001) 1165-1188
6. Berger V.W. Improving the information content of categorical clinical trial data. Controlled Clinical Trials 23 (2002) 502-514
7. Berkson J. Experiences with tests of significance. A reply to R.A. Fisher. Journal of the American Statistical Association 37 (1942) 242-246
8. Berkson J. Tests of significance considered as evidence. Journal of the American Statistical Association 37 (1942) 335-345
9. Bonferroni, C.E. (1935). Il calcolo delle assicurazioni su gruppi di teste. In Studi in Onore del Professore Salvatore Ortu Carboni. Rome, pp. 13-60.
10. Bonferroni C.E. Teoria statistica delle classi e calcolo delle probabilità. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze 8 (1936) 3-62
11. Bulpitt C. Subgroup Analysis. Lancet 2 (1988) 31-34
12. Dubey, S.D. (1985). Adjustment of p-values for multiplicities of intercorrelating symptoms. Proceedings of the VIth International Society for Clinical Biostatisticians, Germany.
13. Dunn O.J. Confidence intervals for the means of dependent, normally distributed variables. Journal of the American Statistical Association 54 (1959) 613-621
14. Dunn O.J. Multiple comparisons among means. Journal of the American Statistical Association 56 (1961) 52-54
15. Edwards A. Likelihood (1972), Cambridge University Press, Cambridge, UK
16. Exner D.V., Dreis D.L., Domanski M.J., and Cohn J.N. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared to white patients with left ventricular dysfunction. New England Journal of Medicine 334 (2001) 1351-1357
17. Fisher L. Carvedilol and the FDA approval process: The FDA paradigm and reflections upon hypotheses testing. Controlled Clinical Trials 20 (1999) 16-39
18. Fisher R.A. Statistical Methods for Research Workers (1925), Oliver and Boyd, Edinburg
19. Fisher R.A. The arrangement of field experiments. Journal of the Ministry of Agriculture September (1926) 503-513
20. Fleiss J.L. Significance tests have a role in epidemiologic research; reactions to A.M. Walker. (Different views). American Journal of Public Health 76 (1986) 559-560
21. Fleiss J.L. Confidence intervals vs. significance tests: Quantitative interpretation. (Letter). American Journal of Public Health 76 (1986) 587
22. Fleiss J.L. Dr. Fleiss response (Letter). American Journal of Public Health 76 (1986) 1033-1034
23. Goodman S.N. Toward evidence-based medical statistics. 1: The p-value fallacy. Annals of Internal Medicine 130 (1999) 995-1004
24. Hill A.B. The environment and disease: Association or causation?. Proceedings of the Royal Society of Medicine 58 (1965) 295-300
25. Hochberg Y., and Liberman U. An extended Simes' test. Statistics and Probability Letters 21 (1994) 101-105
26. Hochberg Y., and Tamhane A.C. Multiple Comparison Procedures (1987), Wiley, New York
27. Hochberg Y., and Westfall P.H. On some multiplicity problems and multiple comparison procedures in biostatistics. In: Sen P.K., and Rao C.R. (Eds). Handbook of Statistics Vol. 18 (2000), Elsevier Sciences 75-113
28. Holm S. A simple sequentially rejective multiple test procedures. Scandinavian Journal of Statistics 6 (1979) 65-70
29. Hommel G. A stepwise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75 (1988) 383-386
30. ISIS-1 Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction-ISIS-1. Lancet ii (1986) 57-66
31. James S. Approximate multinomial probabilities applied to correlated multiple endpoints in clinical trials. Statistics in Medicine (1991) 1123-1135
32. Lang J.M., Rothman K.J., and Cann D.I. That confounded p-value. Epidemiology 9 (1998) 7-8
33. Lee K.L., McNeer F., Starmer C.F., Harris P.J., and Rosari R.A. Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation 61 (1980) 508-515
34. Lewis S.J., Moyé L.A., Sacks F.M., Johnstone D.E., Timmis G., Mitchell J., Limacher M., Kell S., Glasser S.P., Grant J., Davis B.R., Pfeffer M.A., and Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial. Annals of Internal Medicine 129 (1998) 681-689
35. Lewis S.J., Sacks F.M., Mitchell J.S., East C., Glasser S., Kell S., Letterer R., Limacher M., Moyé L.A., Rouleau J.L., Pfeffer M.A., and Braunwald E. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial. Journal of the American College of Cardiology 32 (1998) 140-146
36. Meinert C.L. Clinical Trials Design, Conduct, and Analysis (1986), Oxford University Press, New York
37. Miles J.L. Data torturing. New England Journal of Medicine 329 (1993) 1196-1199
38. Miller R.G. Simultaneous Statistical Inference. 2nd ed. (1981), Springer, New York
39. Moyé L.A. p value interpretation in clinical trials. The case for discipline. Controlled Clinical Trials 20 (1999) 40-49
40. Moyé L.A. Multiple Analyses in Clinical Trials: Fundamentals for Investigators (2003), Springer, New York
41. Moyé L.A., and Abernethy D. Carvedilol in patients with chronic heart failure (Letter). New England Journal of Medicine 335 (1996) 1318-1319
42. Moyé L.A., Davis B.R., and Hawkins C.M. Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. Statistics in Medicine 11 (1992) 1705-1717
43. Moyé L.A., Pfeffer M.A., Wun C.C., Davis B.R., Geltman E., Hayes D., Farnham D.J., Randall O.S., Dinh H., Arnold J.M.O., Kupersmith J., Hager D., Glasser S.P., Biddle T., Hawkins C.M., and Braunwald E. Uniformity of captopril benefit in the post infarction population: Subgroup analysis in SAVE. European Heart Journal 15 Supplement B (1994) 2-8
44. MRFIT Investigators. Multiple risk factor intervention trial. Journal of the American Medical Association 248 (1982) 1465-1477
45. Nester M.R. An applied statistician's creed. Applied Statistics 45 (1996) 4401-4410
46. Neuhauser M., Steinijans V.W., and Bretz F. The evaluation of multiple clinical endpoints with application to asthma. Drug Information Journal 33 (1999) 471-477
47. Neyman J. Outline of a theory of statistical estimation based on the classical theory of probability. Philosophical Transactions of the Royal Society (London), Series A 236 (1937) 333-380
48. Neyman J. L'estimation statistique traitée comme un problème classique de probabilité. Actualités Scientifiques et Industrielles 739 (1938) 25-57
49. Neyman J., and Peason E.S. On the problem of the most efficient tests of statistical hypotheses. Philosophical Transactions of the Royal Society (London), Series A 231 (1933) 289-337
50. O'Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics 40 (1984) 1079-1089
51. Packer, M. (2000). Presentation of the results of the Prospective Randomized Amlodipine Survival Evaluation-2 Trial (PRAISE-2) at the American College of Cardiology Scientific Sessions, Anaheim, California, March 15, 2000.
52. Packer M., Cohn J.N., and Ccolucci W.S. Response to Moyé and Abernethy. New England Journal of Medicine 335 (1996) 1318-1319
53. Packer, M., O'Connor, C.M., Ghali, J.K., Pressler, M.L., Carson, P.E., Belkin, R.N., Miller, R.P., Neuberg, G.W., Frid, D., Wertheimer, J.H., Cropp, A.B., DeMets, D.L., for the Prospective Randomized Amlodipine Survival Evaluation Study Group (1996). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New England Journal of Medicine 335, 1107-1114.
54. Peduzzi P., Wittes J., Deter K., and Holford T. Analysis as-randomized and the problem of non-adherence; an example from the veterans affairs randomized trial of coronary artery bypass surgery. Statistics in Medicine 12 (1993) 1185-1195
55. Pedersen, T.R., Olsson, A.G., Ole Færgeman, Kjekshus, J., Hans Wedel, H., Kåre Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., Miettinen, T., Christophersen, B., Tobert, J.A., Musliner, T.A., Cook, T.J., for the Scandinavian Simvastatin Survival Study Group. (1998). Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97, 1453-1460.
56. Peto R., Collins R., and Gray R. Large-scale randomized evidence: Large, simple trials and overviews of trials. Journal of Clinical Epidemiology 48 (1995) 23-40
57. Pfeffer M.A., Braunwald E., Moyé L.A., Basta L., Brown E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., Klein M., Lamas G.A., Packer M., Roleau J., Routeau J., Rutherford J., Wertheimer J.H., and Hawkins C.M. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. New England Journal of Medicine 327 (1992) 669-677
58. Piantadosi S. Clinical Trials: A Methodologic Perspective (1997), Wiley, New York
59. Poole C. Beyond the confidence interval. American Journal of Public Health 77 (1987) 195-199
60. Pytkowsi, W. (1932). The dependence of the income in small farms upon their area, the outlay and the capital invested in cows, (Polish, English summaries), Monograph no. 31 of series Bioblioteka Pulawska, Publ. Agri. Res. Inst. Pulasy, Poland.
61. Reitmeir P., and Wassmer G. One sided multiple endpoints testing in two-sample comparisons. Communications in Statistics: Simulation and Computation 25 (1996) 99-117
62. Rothman R.J. No adjustments are needed for multiple comparisons. Epidemiology 1 (1990) 43-46
63. Sacks F.M., Moyé L.A., Davis B.R., Cole T.B., Rouleau J.L., Nash D., Pfeffer M.A., and Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 97 (1998) 1446-1452
64. Sacks F.M., Pfeffer M.A., Moyé L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.-C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 335 (1996) 1001-1009
65. Sankoh A.J., Huque M.F., and Dubey S.D. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Statistics in Medicine 16 (1997) 2229-2242
66. Senn S. Statistical Issues in Drug Development (1997), Wiley, Chichester Section 15.2.1
67. Shaffer J.P. Modified sequentially rejective multiple test procedures. Journal of the American Statistical Association 81 (1986) 826-831
68. Simes R.J. An improved Bonferroni procedure for multiple tests of significance. Biometrika 73 (1986) 819-827
69. Stolberg, S.G. Should a pill be colorblind? New York Times. Week in Review. May 13, 2001, p. 1.
70. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 345 (2001) 494-502
71. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with CAD and a broad range of initial cholesterol levels. New England Journal of Medicine 339 (1998) 1349-1357
72. The SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug therapy in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). Journal of the American Medical Association 265 (1991) 3255-3264
73. Transcript of the Cardiovascular and Renal Drugs Advisory Committee to the FDA Captopril. February 16, 1993.
74. Tukey J.W., Ciminera J.L., and Heyse J.F. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41 (1985) 295-301
75. Wald A. Statistical Decision Functions (1950), Wiley, New York
76. Walker A.M. Significance tests represent consensus and standard practice (Letter). American Journal of Public Health 76 (1986) 1033 (See also Journal erratum; 76, 1087)
77. Walker A.M. Reporting the results of epidemiologic studies. American Journal of Public Health 76 (1986) 556-558
78. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1996) 1440-1445
79. Westfall P.H., Ho S.Y., and Prillaman B.A. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. Journal of Biopharmaceutical Statistics 11 (2001) 125-138
80. Westfall, P.H., Wolfinger, R.D. (2000). Closed Multiple Testing Procedures and PROC MULTITEST. SAS Observations, July 2000.
81. Westfall P.H., and Young S.S. Resampling Based Multiple Testing: Examples and Methods for P-Value Adjustment (1993), Wiley, New York
82. Yancy, C.W., Fowler, M.B., Ccolucci, W.S., Gilber, E.M., Brisstow, M.R., Cohn, J.N., Luka, M.A., Young, S.T., Packer, M. for the US Carvedilol Heart Failure Study Group. (2001). Race and response to adrenergic blockade with carvedilol in patients with chronic heart failure. New England Journal of Medicine 334, 1358-65.
83. Yusuf S., Wittes J., Probstfield J., and Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association 266 (1991) 93-98
84. Zhang J., Qwuan H., Ng J., and Stapanavage M.E. Some statistical methods for multiple endpoints in clinical trials. Controlled Clinical Trials 18 (1997) 204-221